Modality
Small Molecule
MOA
Anti-Tau
Target
TROP-2
Pathway
Fibrosis
Crohn's
Development Pipeline
Preclinical
Sep 2024
→ Jun 2028
PreclinicalCurrent
NCT05461729
1,431 pts·Crohn's
2024-09→2028-06·Not yet recruiting
1,431 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-06-212.2y awayInterim· Crohn's
Trial Timeline
Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
Preclinical
Not yet…
Catalysts
Interim
2028-06-21 · 2.2y away
Crohn's
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05461729 | Preclinical | Crohn's | Not yet recr... | 1431 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 |